Baggott C, Reddel HK, Hardy J, et al. - In the 2019 update of the Global Initiative for Asthma (GINA), symptom-driven low-dose inhaled corticosteroid-formoterol has been recommended as one of the preferred treatment regimens at steps 1 and 2, researchers here sought for data on patient preferences for this regimen. They assessed a subgroup of participants in the PRACTICAL study, a randomized control trial comparing symptom-driven budesonide-formoterol with maintenance budesonide plus as-needed terbutaline, via surveying them on treatment preferences, satisfaction, beliefs and experience at their final study visit. The survey was completed by 306 of 407 eligible participants (75%). Observations revealed that most participants preferred the regimen to which they had been randomized, however, those randomized to budesonide-formoterol as needed exhibited this association much strongly, intimating that most patients favored as-needed corticosteroid-formoterol therapy if they had undergone it.